Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Pfizer Requesting Cancer Drug Approval

June 1, 2011 6:46 am | News | Comments

Pfizer Inc. said it asked European Union regulators to approve its drug candidate axitinib as a treatment for advanced renal cell carcinoma in patients who haven't been helped by other therapies.


FDA Approves DIFICID Tablets

June 1, 2011 5:50 am | News | Comments

The FDA has approved Optimer Pharmaceuticals' antibacterial drug DIFICID (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea in adults.


Mymetics’ Phase I Study on HIV Vaccine MYM-V101

May 31, 2011 1:14 pm | News | Comments

Mymetics Corporation reports its HIV-1 (Human Immunodeficiency Virus type 1) vaccine proved to be safe, well-tolerated, and demonstrated a high level of immunogenicity in a Phase I trial of 24 healthy women.


Researchers Reveal Laboratory Mouse Details

May 31, 2011 1:10 pm | News | Comments

Mice and humans share about 95% of their genes, and mice are recognized as the leading experimental model for studying human biology and disease.


FDA Approves Combivir

May 31, 2011 1:06 pm | News | Comments

The U.S. Food and Drug Administration (FDA) approved TEVA’s Abbreviated New Drug Application (ANDA) to market a generic version of ViiV Healthcare Company’s HIV treatment, Combivir Tablets (Lamivudine and Zidovudine).


InSite Vision Joins Lawsuit Against Sandoz

May 31, 2011 1:03 pm | News | Comments

InSite Vision Incorporated reported it will join Merck and Pfizer Inc. in filing a patent infringement lawsuit against Sandoz Inc.


Aegerion Pharma Posts New Lomitapide Study Data

May 31, 2011 12:55 pm | News | Comments

Aegerion Pharmaceuticals Inc. presented further late-stage study data for its drug candidate lomitapide on May 31, saying the drug is safe for lowering "bad" cholesterol and patients who continued to use it for more than a year maintained reductions.


Excelimmune Completes $10.5 Million Series B Financing

May 31, 2011 12:36 pm | News | Comments

Excelimmune, Inc. announced that it will use the proceeds of $10.5 million in Series B financing  to advance Staphguard, a human recombinant polyclonal antibody (HRPA) candidate against methicillin-resistant Staphylococcus aureus (MRSA), toward the clinic and improve the company’s discovery platform and  proof-of-principle for its manufacturing systems.


Molecular Blood Blotting Mystery Solved

May 31, 2011 12:29 pm | News | Comments

In a new study, researchers describe a chemical interaction between a clotting factor and a cell membrane that has baffled scientists for decades.


Microplate Software Protocol

May 31, 2011 8:07 am | Product Releases | Comments

Thermo Fisher Scientific Inc. introduced a downloadable software protocol library for its Multiskan GO microplate spectrophotometer. There are currently 20 ready-made protocols available to cover a wide variety of photometric applications.


DsiRNA Screening

May 31, 2011 7:52 am | Product Releases | Comments

Integrated DNA Technologies offers a comprehensive range of customizable products for RNA interference applications. The Screening Dicer-substrate siRNA provides researchers with a cost-effective and quick solution for their RNAi requirements.


Noncoding RNA May Promote Alzheimer's

May 31, 2011 7:41 am | News | Comments

Researchers have pinpointed a small RNA that spurs cells to manufacture a particular splice variant of a key neuronal protein, potentially promoting Alzheimer's disease or other types of neurodegeneration.


SUNY Buffalo Picks Sage-N for Proteomics Research

May 31, 2011 7:34 am | News | Comments

Sage-N Research, Inc. announced that the State University of New York at Buffalo’s pharmaceutical sciences research group has chosen the SORCERER platform to assist with its advanced proteomics research.


Gene Therapy Fails in Phase 3 Trial

May 31, 2011 7:24 am | News | Comments

Despite showing promising results in a recent phase 2 trial, administration of a novel gene therapy to enhance the growth of new blood vessels in people with critical limb ischaemia, does not reduce amputation or death.


DTC Genetic Tests Inaccurate

May 31, 2011 7:10 am | News | Comments

Geneticists from the European Society of Human Genetics have found that direct-to-consumer genetic tests give inaccurate predictions of disease risks and believe that some of them should be banned.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.